Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in regions of inflammation selectively targeting and ...

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed ...

U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026 - Patient dosing expected to begin in Australia in Q4 ...

Biologic medication for ulcerative colitis may work better for you if other treatments don’t. Learn 10 important facts about ...

The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...

PDS Biotechnology (PDSB) announced final topline survival data from its VERSATILE-002 Phase 2 clinical trial. VERSATILE-002 evaluated PDS0101 + Keytruda in patients with HPV16-positive first-line ...

Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or ...

CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues.

It is given as a subcutaneous injection (under the skin) once weekly. Learn more about where the best place to inject Zepbound is and what a typical dosing schedule looks like for the drug.

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients ...